Skip to main content
Clinical Fact Sheet

Foundayo®

Oral tablet. GLP-1 Receptor Agonist (oral, non-peptide).

Medically reviewed by Dr. Sarah Chen, PharmD • Last updated April 2026

Check Eligibility
Foundayo orforglipron medication product image

FDA Status

Approved

Manufacturer

Eli Lilly

Generic Name

orforglipron

Typical Cost

$149/mo

Delivery Method

Oral tablet

What is Foundayo?

Foundayo is an oral GLP-1 receptor agonist medication manufactured by Eli Lilly, FDA-approved in April 2026 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Its active ingredient, orforglipron, works as a non-peptide small molecule that activates the GLP-1 receptor to reduce appetite, increase satiety, and promote weight loss — without the absorption challenges that require peptide-based oral GLP-1s to be taken on an empty stomach. In the ATTAIN-1 clinical trial, patients taking the 36 mg dose lost an average of 12.4% of body weight over 72 weeks; 59.6% of participants lost at least 10% of their body weight. Foundayo is taken as a once-daily oral tablet at any time of day, with or without food and without water restrictions. As of April 2026, Foundayo costs approximately $149 per month at retail without insurance, with further reductions available through Eli Lilly’s savings programs and insurance coverage. Foundayo is the only GLP-1 weight-loss medication with no meal-timing restrictions whatsoever.

Overview

Approved April 2026. The only oral GLP-1 for weight loss that can be taken any time of day without food or water restrictions. A non-peptide small molecule, different from semaglutide-based orals.

Pricing

Typical retail pricing for Foundayo is approximately $149/mo without insurance. Compounded alternatives may be available at lower cost through telehealth providers.

How It Works

Foundayo (orforglipron) works as a GLP-1 Receptor Agonist (oral, non-peptide). It mimics natural hormones that regulate appetite, blood sugar, and satiety signals.

Common Side Effects

  • Nausea (typically worst during dose escalation)
  • Diarrhea and constipation
  • Headache and fatigue
  • Reduced appetite (the intended therapeutic effect)

How It Compares

Foundayo is one of two oral GLP-1 weight-loss pills now available. The other is Wegovy Pill (oral semaglutide from Novo Nordisk). The critical difference: Foundayo can be taken any time without food restrictions; oral Wegovy requires a 30-minute fasting window before each dose. See Foundayo vs Wegovy Pill for the full comparison.

Compared to injectable options, Foundayo’s 12.4% average weight loss sits below Zepbound (20–22%) and injectable Wegovy (~15%). For patients considering format vs. efficacy trade-offs, see oral vs injectable GLP-1s.

Frequently Asked Questions

How much does Foundayo cost?

Foundayo has a list price of approximately $149 per month as of April 2026, making it one of the most affordable branded GLP-1 medications available — comparable in price to compounded semaglutide and significantly cheaper than injectable alternatives like Wegovy ($1,349/month retail) or Zepbound ($1,059/month retail). With commercial insurance and the Eli Lilly savings card, copays may be even lower — potentially as low as $25/month for eligible patients. Eli Lilly deliberately positioned Foundayo’s pricing to undercut compounded alternatives and increase access for patients who can’t afford or don’t want to use injections. The $149/month list price means that even uninsured patients can access a brand-name, FDA-approved GLP-1 without relying on manufacturer assistance programs or compounding. This pricing strategy also puts direct pressure on Wegovy Pill’s NovoCare pricing, which starts at $149/month as well. For cost-sensitive patients seeking an oral GLP-1 for weight loss, Foundayo’s combination of low price point and convenience (no food restrictions) makes it a compelling option.

Is Foundayo a pill or injection?

Foundayo is an oral tablet taken once daily — no injections, no needles, no special timing requirements. This distinguishes it from all injectable GLP-1 options (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Trulicity) and from older oral semaglutide options that have strict meal-timing restrictions. Rybelsus and Wegovy Pill, the two other oral GLP-1 tablets, both require an empty stomach and a 30-minute fasting window because they use a peptide formulation that needs specific stomach conditions to absorb. Foundayo uses orforglipron — a non-peptide small molecule — which is chemically stable in the digestive environment and doesn’t require any special conditions for absorption. In practical terms, this means you can take Foundayo whenever it fits your routine: with breakfast, after dinner, at noon, or any other time. The ATTAIN-1 clinical trial, which confirmed 12.4% average weight loss at the 36 mg dose over 72 weeks, was conducted with this no-restriction protocol. For patients who have struggled with the fasting requirements of other oral GLP-1s, Foundayo removes that barrier entirely.

How does Foundayo compare to Wegovy Pill?

Both Foundayo and Wegovy Pill are oral GLP-1 weight-loss tablets launched in 2025–2026, but they differ in several important ways. The most practical difference is convenience: Foundayo (orforglipron) can be taken any time of day with or without food; Wegovy Pill (oral semaglutide) requires taking it first thing in the morning on an empty stomach followed by a 30-minute fast. Mechanistically, Foundayo is a non-peptide small molecule — a fundamentally different drug class — while Wegovy Pill uses the same semaglutide peptide found in injectable Wegovy. Clinical data slightly favors Wegovy Pill: 13.6% mean weight loss in OASIS 4 versus 12.4% in ATTAIN-1 for Foundayo at 36 mg, though these are different trials. Wegovy Pill also benefits from semaglutide’s longer clinical track record, including cardiovascular data from the SELECT trial. Both are priced comparably ($149–299/month). See the full Foundayo vs Wegovy Pill comparison for the complete head-to-head.

When did Foundayo get FDA approval?

Foundayo (orforglipron) received FDA approval in April 2026 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, sleep apnea, or cardiovascular disease. The approval was based on the ATTAIN-1 clinical trial, which demonstrated 12.4% mean weight loss at the 36 mg dose over 72 weeks, with 59.6% of participants losing ≥10% of body weight and 39.6% losing ≥15%. Foundayo is the first non-peptide oral GLP-1 receptor agonist approved for weight loss by the FDA — representing a distinct pharmacological class from peptide-based oral options like Wegovy Pill (oral semaglutide) and Rybelsus. The non-peptide small molecule format is what enables its take-anytime, no-food-restriction dosing. Eli Lilly also has Foundayo in development for Type 2 diabetes management, with separate trial data pending regulatory review.

Does insurance cover Foundayo?

Insurance coverage for Foundayo is actively rolling out as of April 2026, given its very recent FDA approval. Commercial insurance plans are beginning to add it to formularies, particularly under anti-obesity medication benefits, but coverage decisions vary significantly by insurer and plan type. Many plans that cover Wegovy or Zepbound are expected to add Foundayo as an alternative option — especially given its low list price, which creates favorable cost economics for payers. Prior authorization will typically be required, consistent with standard practice for GLP-1 weight-loss medications. Eligibility criteria generally include BMI ≥30 or ≥27 with comorbidities, plus documentation of treatment rationale. The important context is that even without insurance, Foundayo’s $149/month list price is already more affordable than most competing branded GLP-1 alternatives. Unlike Wegovy injection ($1,349/month retail) or Zepbound ($1,059/month retail), Foundayo’s list price requires no special savings program for most patients to afford. Check your plan’s formulary with the medication name “orforglipron” or “Foundayo” for current coverage status.

Is Foundayo as effective as injectable GLP-1s?

Foundayo’s 12.4% average weight loss in the ATTAIN-1 trial is clinically meaningful — for a 220-pound patient, that represents approximately 27 pounds of average weight loss. However, it is lower than injectable alternatives: injectable Wegovy achieved 14.9% in STEP-1 and Zepbound achieved 20.9% in SURMOUNT-1. The gap versus Zepbound is particularly notable: at the 15 mg dose, tirzepatide produces nearly 9% more average weight loss than Foundayo. That said, the efficacy comparison must be weighed against convenience and adherence. Foundayo’s take-anytime, no-food-restriction format eliminates the primary adherence barriers that undermine other oral GLP-1s. Research consistently shows that adherence — consistently taking the medication as prescribed — is the single biggest driver of real-world outcomes. For patients who would skip or improperly take injectable or fasting-dependent oral GLP-1s, Foundayo’s easier routine may deliver better real-world results than theoretically superior medications they use inconsistently. For patients who specifically want maximum weight loss and are comfortable with weekly injections, Zepbound remains the highest-efficacy option.

Keep Reading

Frequently Asked Questions

How much does Foundayo cost?
Foundayo has a list price of approximately $149 per month as of April 2026, making it one of the most affordable branded GLP-1 medications available — comparable in price to compounded semaglutide and significantly cheaper than injectable alternatives like Wegovy ($1,349/month retail) or Zepbound ($1,059/month retail). With commercial insurance and the Eli Lilly savings card, copays may be even lower — potentially as low as $25/month for eligible patients. Eli Lilly deliberately positioned Foundayo's pricing to undercut compounded alternatives and increase access for patients who can't afford or don't want to use injections. The $149/month list price means that even uninsured patients can access a brand-name, FDA-approved GLP-1 without relying on manufacturer assistance programs or compounding. This pricing strategy also puts direct pressure on Wegovy Pill's NovoCare pricing, which starts at $149/month as well. For cost-sensitive patients seeking an oral GLP-1 for weight loss, Foundayo's combination of low price point and convenience (no food restrictions) makes it a compelling option.
Is Foundayo a pill or injection?
Foundayo is an oral tablet taken once daily — no injections, no needles, no special timing requirements. This distinguishes it from all injectable GLP-1 options (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Trulicity) and from older oral semaglutide options that have strict meal-timing restrictions. Rybelsus and Wegovy Pill, the two other oral GLP-1 tablets, both require an empty stomach and a 30-minute fasting window because they use a peptide formulation that needs specific stomach conditions to absorb. Foundayo uses orforglipron — a non-peptide small molecule — which is chemically stable in the digestive environment and doesn't require any special conditions for absorption. In practical terms, this means you can take Foundayo whenever it fits your routine: with breakfast, after dinner, at noon, or any other time. The ATTAIN-1 clinical trial, which confirmed 12.4% average weight loss at the 36 mg dose over 72 weeks, was conducted with this no-restriction protocol. For patients who have struggled with the fasting requirements of other oral GLP-1s, Foundayo removes that barrier entirely.
How does Foundayo compare to Wegovy Pill?
Both Foundayo and Wegovy Pill are oral GLP-1 weight-loss tablets launched in 2025–2026, but they differ in several important ways. The most practical difference is convenience: Foundayo (orforglipron) can be taken any time of day with or without food; Wegovy Pill (oral semaglutide) requires taking it first thing in the morning on an empty stomach followed by a 30-minute fast. Mechanistically, Foundayo is a non-peptide small molecule — a fundamentally different drug class — while Wegovy Pill uses the same semaglutide peptide found in injectable Wegovy. Clinical data slightly favors Wegovy Pill: 13.6% mean weight loss in OASIS 4 versus 12.4% in ATTAIN-1 for Foundayo at 36 mg, though these are different trials. Wegovy Pill also benefits from semaglutide's longer clinical track record, including cardiovascular data from the SELECT trial. Both are priced comparably ($149–299/month). See the full Foundayo vs Wegovy Pill comparison for the complete head-to-head.
When did Foundayo get FDA approval?
Foundayo (orforglipron) received FDA approval in April 2026 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, sleep apnea, or cardiovascular disease. The approval was based on the ATTAIN-1 clinical trial, which demonstrated 12.4% mean weight loss at the 36 mg dose over 72 weeks, with 59.6% of participants losing ≥10% of body weight and 39.6% losing ≥15%. Foundayo is the first non-peptide oral GLP-1 receptor agonist approved for weight loss by the FDA — representing a distinct pharmacological class from peptide-based oral options like Wegovy Pill (oral semaglutide) and Rybelsus. The non-peptide small molecule format is what enables its take-anytime, no-food-restriction dosing. Eli Lilly also has Foundayo in development for Type 2 diabetes management, with separate trial data pending regulatory review.
Does insurance cover Foundayo?
Insurance coverage for Foundayo is actively rolling out as of April 2026, given its very recent FDA approval. Commercial insurance plans are beginning to add it to formularies, particularly under anti-obesity medication benefits, but coverage decisions vary significantly by insurer and plan type. Many plans that cover Wegovy or Zepbound are expected to add Foundayo as an alternative option — especially given its low list price, which creates favorable cost economics for payers. Prior authorization will typically be required, consistent with standard practice for GLP-1 weight-loss medications. Eligibility criteria generally include BMI ≥30 or ≥27 with comorbidities, plus documentation of treatment rationale. The important context is that even without insurance, Foundayo's $149/month list price is already more affordable than most competing branded GLP-1 alternatives. Unlike Wegovy injection ($1,349/month retail) or Zepbound ($1,059/month retail), Foundayo's list price requires no special savings program for most patients to afford. Check your plan's formulary with the medication name "orforglipron" or "Foundayo" for current coverage status.
Is Foundayo as effective as injectable GLP-1s?
Foundayo's 12.4% average weight loss in the ATTAIN-1 trial is clinically meaningful — for a 220-pound patient, that represents approximately 27 pounds of average weight loss. However, it is lower than injectable alternatives: injectable Wegovy achieved 14.9% in STEP-1 and Zepbound achieved 20.9% in SURMOUNT-1. The gap versus Zepbound is particularly notable: at the 15 mg dose, tirzepatide produces nearly 9% more average weight loss than Foundayo. That said, the efficacy comparison must be weighed against convenience and adherence. Foundayo's take-anytime, no-food-restriction format eliminates the primary adherence barriers that undermine other oral GLP-1s. Research consistently shows that adherence — consistently taking the medication as prescribed — is the single biggest driver of real-world outcomes. For patients who would skip or improperly take injectable or fasting-dependent oral GLP-1s, Foundayo's easier routine may deliver better real-world results than theoretically superior medications they use inconsistently. For patients who specifically want maximum weight loss and are comfortable with weekly injections, Zepbound remains the highest-efficacy option. ---
Affiliate Disclosure: GLP-1 Price Guide may receive a commission if you choose to utilize the services or tools linked on this page. Our research team maintains strict editorial independence to ensure objective pricing data.